Mobile Health App for Chronic Wound Management (Preprint)

2021 ◽  
Author(s):  
David Reifs ◽  
Ramon Reig Bolaño ◽  
Francesc Garcia Cuyas ◽  
Marta Casals Zorita ◽  
Sergi Grau Carrion

BACKGROUND Chronic ulcers, and especially ulcers affecting the lower extremities and their protracted evolution, are a health problem with significant socio-economic repercussions. The patient's quality of life often deteriorates, leading to serious personal problems for the patient and, in turn, major care challenges for healthcare professionals. Our study proposes a new approach for assisting wound assessment and criticality with an integrated framework based on a Mobile App and a Cloud platform, supporting the practitioner and optimising organisational processes. This framework, called Clinicgram, uses a decision-making support method, such as morphological analysis of wounds and artificial intelligence algorithms for feature classification and a system for matching similar cases via an easily accessible and user-friendly mobile app, and assesses the clinician to choose the best treatment. OBJECTIVE The main objective of this work is to evaluate the impact of the incorporation of Clinicgram, a mobile App and a Cloud platform with Artificial Intelligence algorithms to help the clinician as a decision support system to assess and evaluate correct treatments. Second objective evaluates how the professional can benefit from this technology into the real clinical practice, how it impacts patient care and how the organisation’s resources can be optimised. METHODS Clinicgram application and framework is a non-radiological clinical imaging management tool that is incorporated into clinical practice. The tool will also enable the execution of the different algorithms intended for assessment in this study. With the use of computer vision and supervised learning techniques, different algorithms are implemented to simplify a practitioner's task of assessment and anomaly spotting in clinical cases. Determining the area of interest of the case automatically and using it to assess different wound characteristics such as area calculation and tissue classification, and detecting different signs of infection. An observational and an objective study have been carried out that will allow obtaining clear indicators of the level of usability in clinical practice. RESULTS A total of 2,750 wound pictures were taken by 10 nurses for analysis during the study from January 2018 to November 2021. Objective results have been obtained from the use and management of the application, important feedback from professionals with a score of 5.55 out of 7 according to the mHealth App Usability Questionnaire. It has also been possible to collect the most present type of wound according to Resvech 2.0 of between 6 and 16 points of severity, and highlight the collection of images of between 0 and 16 cm2 of area 88%, with involvement of subcutaneous tissue 53.21%, with the presence of granulated tissue 59.16% and necrotic 30.29% and with a wet wound bed 61.54%. The usage of app to upload samples increase from 31 to 110 samples per month from 2018 to 2021. CONCLUSIONS Our real-world assessment demonstrates the effectiveness and reliability of the wound assessment system, increasing professional efficiency, reducing data collection time during the visit and optimising costs-effectivity in the healthcare organisation by reducing treatment variability. Also, the comfort of the professional and patient. Incorporating a tool such as Clinicgram into the chronic wound assessment and monitoring process adds value, reduction of errors and improves both the clinical practice process time, while also improving decision-making by the professional and consequently having a positive impact on the patient's wound healing process.


2016 ◽  
Vol 25 (1) ◽  
pp. 43-47 ◽  
Author(s):  
Christopher James Ryan ◽  
Sascha Callaghan

Objectives: The Mental Health Act 2007 (NSW) ( MHA) was recently reformed in light of the recovery movement and the United Nations Convention on the Rights of Persons with Disabilities. We analyse the changes and describe the impact that these reforms should have upon clinical practice. Conclusions: The principles of care and treatment added to the MHA place a strong onus on clinicians to monitor patients’ decision-making capacity, institute a supported decision-making model and obtain consent to any treatment proposed. Patients competently refusing treatment should only be subject to involuntary treatment in extraordinary circumstances. Even when patients incompetently refuse treatment, clinicians must make every effort reasonably practicable to tailor management plans to take account of any views and preferences expressed by them or made known via friends, family or advance statements.



Author(s):  
Marcel Ioan Bolos ◽  
Victoria Bogdan ◽  
Ioana Alexandra Bradea ◽  
Claudia Diana Sabau Popa ◽  
Dorina Nicoleta Popa

The present paper aims to analyze the impairment of tangible assets with the help of artificial intelligence. Stochastic fuzzy numbers have been introduced with a dual purpose: on one hand to estimate the cash flows generated by tangible assets exploitation and, on the other hand, to ensure the value ranges stratifications that define these cash flows. Estimation of cash flows using stochastic fuzzy numbers was based on cash flows generated by tangible assets in previous periods of operation. Also, based on the Lagrange multipliers, were introduced: the objective function of minimizing the standard deviations from the recorded value of the cash flows generated by the tangible assets, as well as the constraints caused by the impairment of tangible assets identification according to which the cash flows values must be equal to the annual value of the invested capital. Within the determination of the impairment value and stratification of the value ranges determined by the cash flows using stochastic fuzzy numbers, the impairment of assets risk was identified. Information provided by impairment of assets but also the impairment risks, is the basis of the decision-making measures taken to mitigate the impact of accumulated impairment losses on company’s financial performance.





2020 ◽  
Vol 46 (7) ◽  
pp. 478-481 ◽  
Author(s):  
Joshua James Hatherley

Artificial intelligence (AI) is expected to revolutionise the practice of medicine. Recent advancements in the field of deep learning have demonstrated success in variety of clinical tasks: detecting diabetic retinopathy from images, predicting hospital readmissions, aiding in the discovery of new drugs, etc. AI’s progress in medicine, however, has led to concerns regarding the potential effects of this technology on relationships of trust in clinical practice. In this paper, I will argue that there is merit to these concerns, since AI systems can be relied on, and are capable of reliability, but cannot be trusted, and are not capable of trustworthiness. Insofar as patients are required to rely on AI systems for their medical decision-making, there is potential for this to produce a deficit of trust in relationships in clinical practice.



2019 ◽  
Vol 33 (2) ◽  
pp. 31-50 ◽  
Author(s):  
Ajay Agrawal ◽  
Joshua S. Gans ◽  
Avi Goldfarb

Recent advances in artificial intelligence are primarily driven by machine learning, a prediction technology. Prediction is useful because it is an input into decision-making. In order to appreciate the impact of artificial intelligence on jobs, it is important to understand the relative roles of prediction and decision tasks. We describe and provide examples of how artificial intelligence will affect labor, emphasizing differences between when the automation of prediction leads to automating decisions versus enhancing decision-making by humans.



2017 ◽  
Vol 13 (10) ◽  
pp. S147 ◽  
Author(s):  
Ali Aminian ◽  
Stacey Clemence ◽  
Jay Alberts ◽  
Philip Schauer ◽  
Stacy Brethauer


1996 ◽  
Vol 1 (3) ◽  
pp. 175-178 ◽  
Author(s):  
Colin Gordon

Expert systems to support medical decision-making have so far achieved few successes. Current technical developments, however, may overcome some of the limitations. Although there are several theoretical currents in medical artificial intelligence, there are signs of them converging. Meanwhile, decision support systems, which set themselves more modest goals than replicating or improving on clinicians' expertise, have come into routine use in places where an adequate electronic patient record exists. They may also be finding a wider role, assisting in the implementation of clinical practice guidelines. There is, however, still much uncertainty about the kinds of decision support that doctors and other health care professionals are likely to want or accept.



Blood ◽  
2021 ◽  
Vol 138 (Supplement 1) ◽  
pp. 4934-4934
Author(s):  
Paul Istasy ◽  
Wen Shen Lee ◽  
Alla Iansavitchene ◽  
Ross Upshur ◽  
Bekim Sadikovic ◽  
...  

Abstract Introduction: The expanding use of Artificial Intelligence (AI) in hematology and oncology research and practice creates an urgent need to consider the potential impact of these technologies on health equity at both local and global levels. Fairness and equity are issues of growing concern in AI ethics, raising problems ranging from bias in datasets and algorithms to disparities in access to technology. The impact of AI on health equity in oncology, however, remains underexplored. We conducted a scoping review to characterize, evaluate, and identify gaps in the existing literature on AI applications in oncology and their implications for health equity in cancer care. Methodology: We performed a systematic literature search of MEDLINE (Ovid) and EMBASE from January 1, 2000 to March 28, 2021 using key terms for AI, health equity, and cancer. Our search was restricted to English language abstracts with no restrictions by publication type. Two reviewers screened a total of 9519 abstracts, and 321 met inclusion criteria for full-text review. 247 were included in the final analysis after assessment by three reviewers. Studies were analysed descriptively, by location, type of cancer and AI application, as well as thematically, based on issues pertaining to health equity in oncology. Results: Of the 247 studies included in our analysis, 150 (60.7%) were based in North America, 57 (23.0%) in Asia, 29 (11.7%) in Europe, 5 (2.1%) in Central/South America, 4 (1.6%) in Oceania, and 2 (0.9%) in Africa. 71 (28.6%) were reviews and commentaries, and 176 were (71.3%) clinical studies. 25 (10.1%) focused on AI applications in screening, 42 (17.0%) in diagnostics, 46 (18.6%) in prognostication, and 7 (2.9%) in treatment. 40 (16.3%) used AI as a tool for clinical/epidemiological research and 87 (35.2%) discussed multiple applications of AI. A diverse range of cancers were represented in the studies, including hematologic malignancies. Our scoping review identified three overarching themes in the literature, which largely focused on how AI might improve health equity in oncology. These included: (1) the potential for AI reduce disparities by improving access to health services in resource-limited settings through applications such as low-cost cancer screening technologies and decision support systems; (2) the ability of AI to mitigate bias in clinical decision-making through algorithms that alert clinicians to potential sources of bias thereby allowing for more equitable and individualized care; (3) the use of AI as a research tool to identify disparities in cancer outcomes based on factors such as race, gender and socioeconomic status, and thus inform health policy. While most of the literature emphasized the positive impact of AI in oncology, there was only limited discussion of AI's potential adverse effects on health equity . Despite engaging with the use of AI in resource-limited settings, ethical issues surrounding data extraction and AI trials in low-resource settings were infrequently raised. Similarly, AI's potential to reinforce bias and widen disparities in cancer care was under-examined despite engagement with related topics of bias in clinical decision-making. Conclusion: The overwhelming majority of the literature identified by our scoping review highlights the benefits of AI applications in oncology, including its potential to improve access to care in low-resource settings, mitigate bias in clinical decision-making, and identify disparities in cancer outcomes. However, AI's potential negative impacts on health equity in oncology remain underexplored: ethical issues arising from deploying AI technologies in low-resources settings, and issues of bias in datasets and algorithms were infrequently discussed in articles dealing with related themes. Disclosures No relevant conflicts of interest to declare.



Sign in / Sign up

Export Citation Format

Share Document